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Abstract
Background: Chronic hepatitis C virus (HCV) infection and associated liver cirrhosis represent a major risk factor for
hepatocellular carcinoma (HCC) development. TGF-b is an important driver of liver fibrogenesis and cancer; however, its
actual impact in human cancer progression is still poorly known. The aim of this study was to investigate the role of HCC-
derived HCV core natural variants on cancer progression through their impact on TGF-b signaling.
Principal Findings: We provide evidence that HCC-derived core protein expression in primary human or mouse hepatocyte
alleviates TGF-b responses in terms or growth inhibition or apoptosis. Instead, in these hepatocytes TGF-b was still able to
induce an epithelial to mesenchymal transition (EMT), a process that contributes to the promotion of cell invasion and
metastasis. Moreover, we demonstrate that different thresholds of Smad3 activation dictate the TGF-b responses in hepatic
cells and that HCV core protein, by decreasing Smad3 activation, may switch TGF-b growth inhibitory effects to tumor
promoting responses.
Conclusion/Significance: Our data illustrate the capacity of hepatocytes to develop EMT and plasticity under TGF-b,
emphasize the role of HCV core protein in the dynamic of these effects and provide evidence for a paradigm whereby a viral
protein implicated in oncogenesis is capable to shift TGF-b responses from cytostatic effects to EMT development.
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Introduction
Epithelial to mesenchymal transition (EMT) is defined as a
process in which epithelial cells lose their phenotypic characteristic
and acquire mesenchymal cell’s features. While EMT is involved
in the context of embryonic development it also plays a role in the
genesis of fibroblasts during organ fibrosis in adult tissues and
might contribute to the metastatic carcinoma development [1].
Indeed, EMT is being increasingly recognized as a crucial step
that promotes cell migration, tumoral invasiveness and metastasis
[2] and has also been implicated recently in cancer stem cell
emergence [3]. In the liver, hepatic stellate cells (HCS) are
considered as the major fibrotic precursor cells that transdiffer-
entiate to fibrogenic, extracellular matrix producing myofibro-
blasts in inflammatory liver tissue upon TGF-b signaling, whereas
hepatocytes undergo apoptosis upon signaling by this cytokine.
However, identification of different fibrogenic populations apart of
resident stellate cells [4] as well as convergent results of recent
studies have challenged the paradigm of HSC as the essential
source of liver myofibroblasts and inferred a prominent role for
hepatocytes in liver fibrogenesis. Indeed, it has been reported
recently that rat or mouse hepatocytes respond both in vitro and in
vivo to TGF-b not only in terms of cell growth inhibition and
apoptosis, but also in terms of induction of EMT [5–7].
Accordingly, it has been shown that TGF-b and laminin 5
transform non invasive hepatocellular carcinoma cells into
invasive cells through induction of a complete EMT [8]. However,
although the molecular mechanisms underlying EMT develop-
ment have been studied extensively, little evidence is available
concerning its physiological functions and relevance in human
pathologies.
One of the mechanisms whereby cells undergo neoplastic
transformation and escape from normal growth control involves
an altered response to the cytostatic effects of TGF-b [9,10].
Furthermore, during the later stages of tumorigenesis, TGF-b
can stimulate invasion mainly through induction of EMT. It is
now generally accepted that TGF-b has a dual role in
oncogenesis and can act as a tumor suppressor or tumor
promoter factor depending on cellular context [11,12], but the
mechanisms involved in the switch of TGF-b responses toward
malignancy are not fully understood. In vivo, it has been shown
that loss of TGF-b signaling significantly decreased tumor
latency and increased the rate of metastasis in several mouse
models [13].
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membrane serine/threonine kinases called receptors type I and
type II, promoting activation of the type I by the type II kinase.
The activated type I receptor then propagates the signal to the
nucleus by phosphorylating Smad2 and Smad3. Once phos-
phorylated, Smad2 and Smad3 associate with the shared partner
Smad4 and the complexes accumulate in the nucleus where
they regulate the expression of TGF-b target genes through
cooperative interactions with transcriptional partners [14,15,16].
Disruption of TGF-b signaling, either via mutational inactivation
of components of the signaling pathway, or by modulation of
their expression or function, is now known to play an important
role in tumor progression. Despite all these evidences, the
clinical implication of TGF-b in metastasis progression remains
unclear.
Chronic hepatitis C virus (HCV) infection and associated liver
cirrhosis represent a major risk factor for hepatocellular carcinoma
(HCC) development, and despite epidemiologic evidence connect-
ing HCV infection to HCC, the clinical impact of this virus on
hepatocarcinogenesis is still unclear [17]. Because HCV RNA
shows high genetic variability, chronic HCV infection results in a
complex population of different but closely related viral variants
commonly referred as quasispecies [18,19]. The non-random
distribution of HCV quasispecies has been observed between
tumoral and non-tumoral liver suggesting the possibility of a
selection of quasispecies with modified functional properties that
could contribute to fibrosis development as well as tumorigenesis
process [20].
The structural component of HCV, HCV core protein has
attracted particular attention after its characterization and various
reports have suggested its potential role in HCV pathogenesis.
Indeed, besides its role in viral RNA packaging, HCV core protein
has been reported to interact with several cellular proteins such as
TNFR [21], PKR [22], Stat3 pRB or p53 [23] leading to
modulation of transcription of genes dependent on these cascades
and consequently to modulation of a number of cellular regulatory
functions. In fact, numerous data have suggested a possible
involvement of HCV core protein in the modulation of cell
proliferation and apoptosis although some results have been
controversial given that core protein has been reported to exhibit
pro or antiapoptotic effects depending on the experimental system
used [24,25]. Moreover these studies were mainly performed using
apoptotic agents from the TNF family and not with TGF-b. This
discrepancy could also be due to genetic heterogeneity of different
HCV genotypes.
We and others have previously demonstrated an interaction
between Smad3 and the HCV core protein [26,27]. Interestingly,
we also observed that different natural core variants isolated from
tumor or non tumor nodules could differently bind Smad3, and
consequently inhibit TGF-b induced Smad3 transcriptional
activity suggesting that the HCV core protein may modulate
TGF-b signaling and its downstream biological responses [27]. We
hypothetised that the molecular heterogeneity of HCV observed in
infected patients could be involved in the clinical course of cancer
development.
Overexpression of TGF-b and concomitant decrease in
hepatocyte growth inhibition is frequently observed in HCC
supporting the notion that TGF-b could play a tumor promoting
role in liver cancer [28]. However, the functional implication of
TGF-b in liver tumorigenesis as well as the implication of EMT in
HCC development are not yet elucidated. Likewise, effects of
oncogenic viral hepatitis B or C proteins on EMT development
have not been studied in the course of hepatocarcinoma process.
Demonstrating interplay between HCV infection and TGF-b
mediated EMT may provide a new model to gain insights in the
mechanisms of liver carcinogenesis.
In this study, we made use of natural HCV core variants
isolated from HCV-related HCC tissues to analyze their impact on
the dual function of TGF-b in a pathophysiogically-relevant
condition. Thus, we investigated the effects of core protein variants
isolated from both tumor or non tumor cirrhotic areas in primary
human hepatocytes; indeed, cirrhosis is a well-known preneoplas-
tic condition, associated in at least 90% of cases of HCC. Using
these variants we provide evidence for a paradigm in which a viral
protein is capable to shift TGF-b responses from cytostatic effects
to EMT development.
Materials and Methods
Materials
Recombinant TGF-b1 and recombinant TRAIL/Apo2L were
purchased from Abcys, the chemical inhibitor of TGF-b signaling
SB-431542 that acts by specifically interfering with the type I
receptor [29] was from Calbiochem, the fluorescent dye DiOC6
(3,39dihexylocarbocyanine iodide) was from Molecular Probes.
Vectors
Full length HCV core sequences were amplified from HCV-
RNA extracted from tumor (T) or cirrhotic (NT) nodules of a
patient (patient B) infected with HCV 1b genotype as previously
described [22]. PCR products were directly sequenced and
inserted into the pcDNA3.1 vector. The sequence of these two
variants has been previously described [27]. The T sequence
differs from the NT one by 2 changes in aa 118 (NRD) and aa
189 (ARV).
(CAGA)9-Luc was kindly provided by Dr J.M. Gauthier. The
expression vectors for HA-TbRI.act, and Flag-TbRImL45.act
were a gift from Dr. Y.E. Zhang [30]. The pRetroSuper-puro
plasmid containing short hairpins RNA antisense against Smad3
was kindly provided by Dr J. Massague ´[ 31]. A pRetroSuper-puro
plasmid containing scramble short hairpins RNA was used as
control. pIRES-GFP was obtained from Stratagene, pCMV-
Renilla-luc was from Promega. Myc-Smad3 expression vector was
previously described [32].
Transgenic mice
To obtain transgenic mice, the HCV core cDNAs isolated from
tumor (T) or cirrhotic nodules (NT) were cloned downstream of
hepatitis B virus regulatory elements and introduced into C57BL/
6 embryos (Institut Clinique de la Souris, Strasbourg, France).
Transgenic mice were identified by subjecting 1 mg of tail DNA to
amplification by PCR.
Cell culture
The human hepatoma cell line Huh7 [33] was maintained in
Dulbecco Modified medium containing 10% fetal calf serum
(FCS). Cells were transfected with the different vectors using the
LipofectAMINE method (Invitrogen) and stable transfectants were
selected by incubating the cells with the antibiotic corresponding
to the selection gene.
Isolation and culture of primary hepatocytes
Primary mouse hepatocytes were isolated by liver perfusion with
a collagenase blend as previously described [34]. After isolation,
hepatocytes were resuspended in Williams medium supplemented
with 10% fetal calf serum, 100 mg/ml streptomycin, 100 U/ml
penicillin, 250 ng/ml fungizone (‘‘plating medium’’) and plated at
the density of 3610
4 cells/cm
2. After 4 hours, serum-containing
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supplemented with 1 mg/ml bovine serum albumin, 100 mg/ml
streptomycin, 100 U/ml penicillin, 250 ng/ml fungizone, and
treated with TGF-b 2 ng/ml or SB431542 1 mM.
Primary human hepatocytes were isolated from the healthy liver
tissue of surgical liver biopsy specimens collected after informed
consent obtained from patient undergoing therapeutic partial
hepatectomy for liver metastasis and benign hepatic tumor.
Collagenase (Sigma Aldrich) perfusion (500 mg/ml, 2.4 mg/ml
CaCl2 in HEPES buffer, pH 7.4) was preceded by extensive
washing of the liver tissue with HEPES/EDTA buffer (pH 7.4)
using a catheter inserted into the vessels on the cut surface of the
resected fragment. Cells were then washed twice and hepatocytes
were separated from nonparenchymatous cells by Percoll
fractionation (30% isotonic Percoll solution, centrifuged at 450 g
for 4 min) and immediately infected at 37uC for 2 h with lentiviral
vectors, washed and plated in Williams medium supplemented as
described elsewhere [35]. Twelve hours later, they were treated or
not with TGF-b or SB431542 for various periods of time.
Lentiviral vectors
TRIP-DU3-CMV-T, TRIP-DU3-CMV-NT and TRIP-DU3-
CMV-Cinv vectors were obtained by substituting GFP in TRIP-
DU3-CMV-GFP with cDNA coding for HCV core sequences. An
inverted core sequence TRIP-DU3-CMV-Cinv was used as a
control.
Vector particles were produced by the transient calcium
phosphate cotransfection of 293T cells as a previously described
[36]. Vector concentrations were normalized according to the p24
(HIV-1 capsid protein) content of supernatants.
Western blotting
Cells were washed twice with PBS and lysed in RIPA buffer
containing 0.5% SDS and Benzon nuclease. Proteins were
quantified with the Bio-Rad protein assay (Bio-Rad, France) and
30 mg of extracts were separated on SDS polyacrylamide gel,
transferred on nitrocellulose membrane and blotted using different
primary antibodies directed against HCV core protein, E-
cadherin, Fibronectin (Santa Cruz Biotechnology), Vimentin
(Chemicon), phospho-Smad3 (Cell signaling), Smad3 (Abcam),
Flag, Myc and HA tags (Sigma). Membranes were revealed using a
chemioluminescence detection kit (ECL Plus, GE Healthcare).
Cell staining
Primary mouse hepatocytes were cultured for 48 h with or
without TGF-b (2 ng/ml) and routine stain hematoxylin-eosin was
performed after fixation of cells with EtOH 70% at 4uC for
15 min.
Immunofluorescence staining
Cells were washed with PBS and fixed with a 4% PFA solution
at 4uC for 20 min followed by methanol permeabilization for
5 min at 220uC. Cells were then incubated with a primary mouse
anti-vimentin, rabbit anti-aSMA, or rabbit anti-E-cadherin
antibody and then with an Alexa Fluor 488 conjugated anti-
mouse antibody and an Alexa Fluor 594 conjugated goat anti-
rabbit antibody (Molecular Probes). They were then stained with
Hoechst and examined by fluorescence microscopy.
Cell proliferation and apoptosis assays
Cell proliferation was assessed by BrdU incorporation (Roche),
cell viability and caspase 3 activity were estimated using a
Celltiter-Glo luminescent cell viability assay or the CaspaseGlo 3/
7 assay respectively (Promega) according to the manufacturer’s
instructions.
Mitochondrial transmembrane potential (DYm) was evaluated
by staining cells (10
6) with the fluorescent dye DiOC6 at a final
concentration of 40 nM for 15 min at 37uC. Cells were
immediately dissociated by trypsin and their fluorescence
estimated by analysis with a FACScan flow cytometer (Becton-
Dickinson) using the FL1 channel [37].
Cell sorting
Flow cytometric analysis and sorting were performed using a
FacsDiva flow cytometer (Becton Dickinson Immunocytometry
Systems). Forward Scatter (FSC) and side scatter (SSC) were
collected through a filter. The GFP signal was collected in the FL1
channel. A light gate was drawn in the SSC versus FSC to exclude
dead cells/debris. Cells in the gate were displayed in a
biparameter histogram (FS versus FL1) and final gating settings
determined to collect the labeled cells. GFP positive cells were
sorted at 5000 cells/sec.
Transcriptional analysis
Cells were cotransfected with vectors coding for the gene of
interest together with the CAGA-luc reporter plasmid and the
Renilla luciferase plasmid to normalize the results. They were
incubated 24 h later in the absence or presence of TGF-b for
another 18 h. Luciferase activity was measured with the Dual
Luciferase reporter assay (Promega) system according to the
manufacturer’s instructions.
Statistical analysis
The significance between the different conditions and their
control was determined by paired Student’s t test using GraphPad
Prism software. A p-value#0.05 was considered significant.
Results
HCV core variants alleviate TGF-b cytostatic responses
and increase TGF-b -mediated EMT in mouse or human
primary hepatocytes
We have previously demonstrated that, when transiently
expressed in hepatic cells, HCV core proteins isolated from tumor
or cirrhotic nodules bind Smad3 differently and that this
interaction inhibits Smad3-dependent transcriptional activity
[27]. To ascertain the physiological relevance of this observation,
we first investigated the impact of such binding on TGF-b
biological responses in hepatocytes isolated from transgenic mice
expressing these HCV tumor (T) or cirrhotic (NT) core variants
under the control of the HBx promoter and which is mostly
expressed in the liver. Hepatocytes were isolated from livers of 2
month old mice and treated or not with TGF-b for 48 hours. We
observed that TGF-b was less potent to inhibit cell proliferation in
hepatocytes isolated from transgenic mice expressing the HCV
core proteins than in hepatocytes isolated from a control mouse
(Fig. 1A). Accordingly, cell viability was less reduced by TGF-b in
cells expressing the core proteins as compared to wild type cells
(Fig. 1B). We also found that expression of the HCV core proteins
inhibited TGF-b-mediated apoptosis as shown by caspase 3
activation, which represents a well-defined hallmark of apoptosis
(Fig. 1C). Interestingly, T core expression decreased TGF-b -
mediated apoptosis or inhibition of cell viability to a higher extent
than the NT core showing a functional significance of the
increased interaction of this core variant with Smad3 [27]. In
order to verify that this HCV core-induced reduction of apoptosis
HCV Core Alters TGF-b Effects
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inducer of apoptosis, TRAIL. Mouse hepatocytes expressing or
not the HCV core proteins respond to TRAIL in a similar manner
in terms of caspase 3 activation suggesting that the overall
apoptosis process was not modified by core expression (Fig. 1D).
This result is in agreement with a previous report indicating that
HCV core leads to TRAIL-induced apoptosis through activation
of the mitochondrial-signaling pathway [38].
Several lines of evidence support the notion that epithelial
cancer cells lose their capacity to respond to TGF-b cytostatic
effects but in some cases retain their ability to respond to other
TGF-b -mediated functions such as EMT. The observation that
HCV core proteins interfere with the ability of TGF-b to execute
cell growth inhibition and cell killing prompted us to consider the
possibility that these proteins might influence TGF-b mediated
EMT. Since recent findings have demonstrated that TGF-b could
induce an EMT in mature mouse hepatocytes in vitro [6,7], we
investigated whether HCV core proteins could modulate the
ability of TGF-b to promote EMT in the same primary
hepatocytes. Contrast microscopy observation revealed that after
treatment for 30 h with TGF-b some hepatocytes acquired a
fibroblast-like morphology suggestive of EMT and that this effect
was more pronounced when these hepatocytes express the core
protein showing that cell plasticity could be increased in mouse
hepatocytes expressing HCV core T protein (Fig. 2A). This
observation was reinforced by videomicroscopy observation (data
not shown). To confirm that these observed phenotypic changes
were reflective of an EMT, we performed immunofluorescence
analyses on hepatocytes isolated from control or from transgenic
mice. In line with previous findings, TGF-b treatment of control
mouse hepatocytes was accompanied by a very strong increase in
the polymerization of the mesenchymal marker alpha smooth
muscle actin (aSMA) consistent with a phenotype of EMT
(Fig. 2B). Interestingly, HCV core proteins and particularly the
T one could increase the aSMA fibers in the absence of
exogenously added TGF-b. To assess whether autocrine release
of TGF-b could be involved in the formation of aSMA stress fibers
in HCV core expressing cells, we used a specific TGFbR1
inhibitor, SB431542. When these expressing cells were treated
with this inhibitor, aSMA fibers completely disappeared, suggest-
ing that the effect of the core protein on EMT development is
mediated by an endogenous production of TGF-b (Fig. 2B). In
accordance, Western blots analyses also showed that E-cadherin
expression, an epithelial marker known to be lost in mesenchymal
cells, was greatly decreased by TGF-b and fully restored by
addition of SB431542 (Fig. 2C).
Figure 1. Expression of HCV core proteins in primary mouse hepatocytes reduce cell growth inhibition and apoptosis induced by
TGF-b. (A,B,C) Mouse hepatocytes obtained from livers of transgenic mice expressing or not HCV core proteins isolated from tumor (T) or cirrhotic
(NT) tissues were treated with TGF-b for 48 h before determination of cell proliferation, estimated by BrDU incorporation (A), cell viability (B) or
caspase 3 activity (C). (D) Cells were treated with TRAIL (20 ng/ml) for 18 h before determination of caspase3 activity. Results represent the mean+/
2SD of triplicates from a representative experiment. * p#0.05, ** p#0.005, *** p#0.0005.
doi:10.1371/journal.pone.0004355.g001
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modulate the magnitude of the negative growth regulatory effects
of TGF-b we also performed experiments in human primary
hepatocytes. Freshly isolated hepatocytes were infected with
lentiviruses coding for the T or NT core variants or an inverted
core sequence as control. Western blot analyses confirmed the
expression of the core proteins (Fig. 3A). Cells were then treated or
not with TGF-b for 96 h prior to analysis for cell viability or
caspase 3 activation. Both TGF-b-mediated decrease in cell
viability (Fig. 3B) and apoptotic responses (Fig. 3C) were alleviated
by HCV core expression confirming the results obtained in mouse
hepatocytes.
Although TGF-b -mediated EMT has been described in
primary mouse or rat hepatocytes as well as in cancerous human
cells, no such study has been yet investigated in primary human
hepatocytes in vitro. Interestingly, we observed that human
hepatocytes could express stress fibers as spikes mainly located in
membrane protrusions under TGF-b treatment (Fig. 4A). Expres-
sion of HCV core proteins increased this TGF-b effect. Here
again expression of the HCV core proteins increased aSMA
Figure 2. Expression of HCV core proteins in primary mouse hepatocytes increase EMT induced by TGF-b. (A) Morphologic changes of
mouse hepatocytes expressing or not HCV T core protein observed after 48 h of culture with or without TGF-b (2 ng/ml). (B) Hepatocytes isolated
from transgenic mice expressing HCV core proteins were treated with TGF-b (2 ng/ml) or SB431542 (1 mM) for 48 h and expression of aSMA was
examined by immunofluorescence using a aSMA antibody. Data are representative of three independent experiments. (C) Hepatocytes isolated from
transgenic mice expressing HCV core proteins were treated with TGF-b or SB431542 for 48 h and expression of E-cadherin was determined by
Western blotting. Anti-p38 western blotting was used as control loading. Data are representative of three independent experiments.
doi:10.1371/journal.pone.0004355.g002
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This effect could involve endogenous TGF-b since it was
completely abolished in the presence of the TGF receptor
inhibitor. To corroborate this result, we studied the expression
of another mesenchymal marker, vimentin. In accordance with the
data obtained with aSMA, we observed that in control
hepatocytes vimentin expression was markedly increased after
TGF-b treatment and that this increase was greater when
hepatocytes expressed the NT core protein and even greater
when T core was expressed (Fig. 4A). Similarly, core proteins
induced vimentin expression and polymerization in the absence of
exogenously added TGF-b. This expression was completely
reversed by the TGFbRI inhibitor suggesting again that
endogenously produced TGF-b could be responsible for this effect.
Western blots analyses evidenced a lower expression of E-
cadherin after TGF-b treatment which was totally recovered in the
presence of the TbRI inhibitor. On the contrary, expression of the
mesenchymal marker fibronectin was greatly increased by TGF-b
(Fig. 4B).
Taken together these data strongly suggest that HCV core
interfere with TGF-b responses in terms of cell growth inhibition
and apoptosis in hepatocytes isolated from transgenic mice as well
as human primary hepatocytes. Remarkably, TGF-b responses, in
terms of EMT are increased by expression of T or NT core protein
variants in both mouse and human hepatocytes. This might reflect
both direct effects of core on TGF-b-induced EMT and reduction
of TGF-b induced apoptosis by the core protein, allowing more
cells to undergo EMT as compared to control cells.
HCV core modulates TGF-b responses in Huh7 cells
In order to dissect the molecular mechanisms activated by the
HCV core protein, we established Huh7 cell lines stably expressing
the T core protein (Fig. 5A). Core protein inhibited TGF-b-
mediated Smad3 transcriptional activity measured by expression
in these cells of a reporter plasmid, which contains CAGA
elements previously shown to be transactivated by TGF-b through
Smad proteins (not shown). Consistent with the results observed in
primary hepatocytes, we found that HCV core protein was able to
decrease the inhibitory effect of TGF-b on cell viability (Fig. 5B).
Similarly, TGF-b -mediated apoptosis was reduced in cells
expressing HCV core as shown by caspase3 activation (Fig. 5C)
or loss of mitochondrial membrane potential, which represents
another early marker of apoptosis (Fig. 5D).
We then determined EMT process in Huh7 cell lines expressing
this core protein. Immunofluorescence studies showed that aSMA
was highly polymerized after TGF-b treatment associated with a
strong decrease of E-cadherin from the cell membranes (Fig. 5E).
aSMA polymerization was increased in core expressing cells.
Interestingly, in the presence of core protein, aSMA fibers
appeared even in the absence of exogenously added TGF-b.
The expression of aSMA was accompanied with anchorage
independent growth, which was observed in the absence of
exogenously added TGF-b in HCV core protein expressing cells
(data not shown).
All together, these data indicate that the effects of HCV core
proteins on TGF-b responses observed in primary hepatocytes
were reproduced in a human hepatoma cell line that could thus
constitute an useful tool to dissect the mechanisms that are
involved in the modulation of TGF-b responses.
We also compared protein core expression in our different
cellular models and in extracts from liver of HCV/HCC patients.
The strongest expression was obtained in human hepatocytes,
which is consistent with an efficient lentiviral transduction. HCV
core protein expression could be also detected in different liver
extracts although at different levels. Interestingly, core expression
in these extracts was comparable to the one observed in mouse
hepatocytes (Fig. 5F).
Differential thresholds of Smad3 activation switch TGF-b
responses from tumor suppression to tumor promotion
To analyze in more details the contribution of Smad
activation in the effects of HCV core on TGF-b responses, we
m a d eu s eo fam u t a n to ft h eT G F - b receptor I, TbRImL45Act
that retains a constitutively active kinase domain but is unable to
induce Smad phosphorylation. Huh7 cells were transfected with
this mutant or with the wild type activated form of TbRI,
together with a plasmid coding for the HCV core and GFP to
detect the transfected cells. Immunofluorescence analysis was
performed 48 h later. A marked polymerization of aSMA was
observed through expression of the constitutively active TbR1
that was similar or even greater when cells also expressed the
HCV core protein (Fig. 6A). This effect was completely lost when
the cells expressed the TbR1 mutant thus demonstrating the
need of activated Smads to initiate EMT.
To confirm this result, we established different independent
Huh7 cell clones, stably expressing or not the HCV core protein,
in which the expression of endogenous Smad3 was reduced by
stable expression of a short-hairpin RNA (shRNA). As expected,
Smad3 depletion prevented TGF-b -induced expression of the
CAGA-luc reporter plasmid in the four independent clones tested,
two of them expressing the core protein (Fig. 7B). Depletion of
Smad3 also blunted the growth inhibitory and apoptotic actions of
TGF-b (Fig. 7C and D). Smad3 inactivation also completely
blocked TGF-b-induced EMT (Fig. 7E), further supporting the
notion that Smad3 plays a crucial role in both tumor suppressor
and pro-metastatic effects of TGF-b in carcinogenesis [39].
We next investigated the possibility that different threshold
levels of Smad3 contribute to the differential effects of TGF-b on
Figure 3. TGF-b cytostatic responses in primary human
hepatocytes expressing HCV core proteins. Freshly isolated cells
were infected with lentiviruses encoding the HCV core protein variants
or an inverted core sequence as control (CTL) (A) Levels of core
expression were estimated by Western blot analysis different time
points after lentivirus transduction. (B, C) Determination of cell viability
(B) or caspase 3 activity (C) was performed after 96 h of treatment with
TGF-b (5 ng/ml). Results represent the mean+/2SD of triplicates from a
representative experiment. * p#0.05, *** p#0.0005.
doi:10.1371/journal.pone.0004355.g003
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of Smad3 in Huh7-shRNA-Smad3 clones (Fig 8A) and determined
in these cells the levels of TGF-b signaling and anti-tumor or pro-
tumor responses. As expected, in cells co-transfected with myc-
Smad3 and CAGA-luc reporter plasmids, increasing Smad3
amounts resulted in the amplification of CAGA-luc transactivation
after TGF-b treatment (Fig. 8B). Strong Smad3 expression led to
consistent luciferase activity in the absence of TGF-b that may be
due to constitutive Smad3 activation. To determine TGF-b
responses in relation to Smad3 expression, Huh7-shRNA-Smad3
cells were also transfected with different amounts of myc-Smad3
plasmid, together with GFP plasmid and sorted on the basis of
GFP expression prior to the addition of TGF-b. Interestingly,
when Smad3 was weakly expressed, TGF-b induced apoptosis was
Figure 4. TGF-b increases EMT in primary human hepatocytes expressing HCV core proteins. (A) Expression of aSMA or Vimentin was
estimated by immunofluorescence analysis after treatment with TGF-b (5 ng/ml) or SB431542 (1 mM). (B) Expression of Fibronectin or E-Cadherin was
estimated by Western blot analysis in the same experimental conditions. Data are representative of three independent experiments.
doi:10.1371/journal.pone.0004355.g004
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comparable in control and TGF-b treated cells. When higher
levels of Smad3 were expressed, decreased cell viability and
increased apoptosis could be observed upon TGF-b addition. This
is consistent with the notion that a high threshold of Smad3 is
necessary to induce TGF-b -mediated anti-tumor responses
(Fig. 8C and D).
The GFP positive cells were also analyzed for aSMA expression
and polymerization after TGF-b treatment. In contrast with
apoptotic data, TGF-b-induced EMT could occur in the context
of low Smad3 expression (Fig. 8E). Taken together, these results
strongly suggest that the amplitude of Smad3 activation may
orientate TGF-b responses towards apoptosis or EMT. These
observations could account for the induction of EMT by the HCV
core protein despite diminution of TGF-b signaling.
Discussion
Our study offers relevant observations regarding both the
mechanisms of HCV-related carcinogenesis and the impact of
TGF-b in human cancer. Indeed, we provide evidence that HCC-
derived HCV core proteins alleviate cell growth inhibition and
apoptosis mediated by TGF-b indicating a biological significance
of the binding of HCV core protein to Smad3. This effect was not
restricted to stably transfected cell lines, since it was also observed
in primary mouse hepatocytes isolated from transgenic animals
expressing the core proteins as well as in primary human
hepatocytes infected in vitro with lentiviruses encoding the same
variants. Thus HCV core protein has also the potential to
negatively impact the cytostatic actions of TGF-b in systems that
may better reflect an in vivo situation. These data are in agreement
with previous results suggesting that Smad3 is a predominant
mediator of TGF-b-induced apoptosis. One attractive possibility
could be that by interacting with Smad3, HCV core protein set a
threshold level of TGF-b signaling that allowed for a modulation
of the magnitude of TGF-b cytostatic responses. Consistent with
this notion, we observed that overexpression of Smad3 could
reverse this effect of HCV core on TGF-b responses in terms of
Smad3 signaling, apoptosis and viability (not shown). Further-
more, this effect of HCV core protein on TGF-b cytostatic
responses appears to be specific because it was not observed when
another apoptotic cytokine such as TRAIL was employed.
Interestingly, in cells expressing HCV core proteins TGF-b was
still able to reduce E-cadherin expression and increase aSMA
expression and polymerization that are hallmarks of EMT. These
alterations were associated with the ability of these cells to exhibit
anchorage independent growth. Importantly, we also observed
that core protein expression was sufficient to provoke EMT
induction in primary hepatocytes. This effect was reverted by
addition of a specific inhibitor of TGF-b I receptor thus
demonstrating a TGF-b dependent effect of core on EMT
development. . These data emphasize a differential effect on
TGF-b actions in terms of apoptosis or EMT.
Different levels of HCV core expression have been observed in
HCV-derived HCC at the mRNA level or in immunohistochem-
istry [40]. Using extracts isolated from livers of HCV/HCC
patients we could detect core expression at the protein level.
Moreover, we have previously shown that core protein extracted
from HCV/HCC tumor tissue could bind Smad3 in GST-pull
down analyses [27] suggesting that perturbation of TGF-b
signaling may also be modulated in vivo. Overall these results
are consistent with the hypothesis that this mechanism could
operate during the development of HCV-induced HCC. Interest-
ingly, both tumor and cirrhotic tissues-derived mutants demon-
strated these biological effects; this likely reflects the preneoplastic
nature of most cirrhotic nodules. However, we did observe a more
pronounced biological effect of tumor-derived mutant on TGF-b
signaling; this might suggest an HCV quasispecies selection in
Figure 6. Smad activation is essential to induce TGF-b -
mediated EMT. (A) Huh7 cells were co-transfected GFP together
with TbR1act or TbR1l45M act plasmids in the presence or absence of
HCV core vector. Immunofluorescence analysis was performed 48 h
later with an anti aSMA antibody. (B) Expression of TbR1act or
TbR1l45M act and HCV core protein were assessed by Western blotting
using anti-HA, anti-Flag or anti-core antibodies respectively.
doi:10.1371/journal.pone.0004355.g006
Figure 5. TGF-b responses in Huh7 cells stably expressing HCV core protein. (A) Expression of HCV core protein determined by Western
blot analysis. (B, C) Cells were treated with TGF-b (5 ng/ml) for 48 h before determination of cell viability (B) or caspase3 activity (C). Results represent
the mean+/2SD of triplicates from a representative experiment. *** p#0.0005 (D) Mitochondrial membrane potential (DYm) was estimated by FACS
analysis in cells treated with TGF-b for 48 h. After staining with DiOC6(3), cells with low fluorescence intensity corresponding to low (DYm) were
gated and their number expressed as a percentage of the total population. A representative experiment is shown. (E) Cells were treated with TGF-b
for 48 h and E-cadherin or aSMA expression was assessed by immunofluorescence analysis. Data are representative of three independent
experiments. (F) Comparative expression of HCV core proteins. Extracts from cultured cells expressing the core protein (Huh7, human or mouse
primary hepatocytes) or from livers of HCV-related HCC patients were analyzed by Western blot. Anti-p38 western blotting was used as control
loading.
doi:10.1371/journal.pone.0004355.g005
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analyses [20,22].
It is commonly accepted that TGF-b signaling pathway plays a
tumor suppressor role thought to be associated with growth
inhibitory and apoptotic responses and a tumor promoter role
thought to reflect the positive effects of TGF-b on tumor cell
invasion. Taken together, our data suggest that HCV core, by
reducing Smad3 signal strength, renders the cells to become less
sensible to tumor suppressive effects of TGF-b although they
retain the tumor promoting effects, assuming that Smad3 may
regulate different targets in function of its level of activation. This
is consistent with the notion that critical signal amplitude may be
needed to evoke a biological effect. In addition to Smad pathways,
non-smad-dependent signal transduction downstream of TGF-b
receptors has been proposed [41,42]. Among them, the MAP
Kinase pathways including ERK, JNK or p38 as well as PI3K/
AKT have been shown to be modulated by TGF-b. Since different
reports have shown that HCV core protein could also modulate
Figure 7. Smad3 depletion prevented TGF-b responses in Huh7 cells expressing or not the HCV core protein. (A) Smad3 expression
determined by Western blot analysis in four independent clones selected after stable transfection with pRetroSuper-shRNA-Smad3 plasmid. Anti-p38
antibody was used as control loading. (B) Different clones were transfected with the CAGA-luc reporter plasmid and treated or not with TGF-b (5 ng/
ml) for 18 h before determination of luciferase activity. Results were normalized with renilla luciferase and represent the mean of triplicates+/2SD.
(C, D) Different clones were treated with TGF-b for 48 h before determination of cell viability (C) or caspase3 activity (D). Results represent the
mean+/2SD of triplicates from a representative experiment. * p#0.05, *** p#0.0005, NS : not significant. (E) Different clones were treated with TGF-b
for 48 h and aSMA polymerization was estimated by immunofluorescence analysis.
doi:10.1371/journal.pone.0004355.g007
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TGF-b responses leading to tumor promotion.
It has been recently reported that hyperactive Ras mediates a
decrease in TGF-b -induced Smad3 phosphorylation in the
COOH-terminal and an increase in JNK-induced Smad3
phosphorylation in the linker region, shifting the TGF-b
pathway from a tumor suppressive to an invasive capacity in
human colorectal as well as hepatic carcinogenesis [43]. Using a
Figure 8. TGF-b responses in Huh7 cells expressing different levels of Smad3. (A) Huh7-shRNA-Smad3 cells (Clone 3) were transfected with
increasing amounts of Myc-Smad3 expression vector together with pCMV renilla luciferase. Smad3 protein expression was evaluated 24 h later by
Western blot analysis using an anti-Myc antibody and loading was normalized with renilla luciferase expression. (B) Huh7-shRNA-Smad3 cells (Clone
3) were cotransfected with the CAGA-luc reporter plasmid and increasing amounts of Myc-Smad3 vector together with pCMV renilla luciferase. 24 h
later, they were treated or not with different doses of TGF-b for 18 h before determination of luciferase activity. Results were normalized with renilla
luciferase and represent the mean+/2SD of triplicates from a representative experiment. (C, D) Huh7-shRNA-Smad3 cells (Clone 3) were transfected
with increasing amounts of Myc-Smad3 vector together with pGFP plasmid and sorted by FACS 24 h later on the basis of GFP expression. Cells were
then cultured for 24 h and treated with different doses of TGF-b for 48 h before determination of cell viability (C) or caspase3 activity (D). * p#0.05, **
p#0.005, *** p#0.0005, NS : not significant. (E) Huh7-shRNA-Smad3 cells (Clone 3) were transfected with increasing amounts of Myc-Smad3 vector
together with pGFP plasmid and sorted 24 h later on the basis of GFP expression. aSMA expression was estimated by immunofluorescence analysis
after treatment with TGF-b (1 ng/ml) for 48 h.
doi:10.1371/journal.pone.0004355.g008
HCV Core Alters TGF-b Effects
PLoS ONE | www.plosone.org 11 February 2009 | Volume 4 | Issue 2 | e4355different model, our results, relevant for human carcinogenesis,
show that reduction of Smad3 activation could account for a
tumor promoting role of TGF-b and raise the possibility that
core protein may trigger one step of liver carcinogenesis by
modulating the balance between TGF-b antitumor or protumor
responses.
Although activation and transdifferentiation of hepatic stellate
cells are still regarded as key mechanisms of fibrogenesis, recent
studies have pointed out that other liver cells, including
hepatocytes may contribute to the pool of myofibroblasts in
fibrosing liver. Our results showing that TGF-b is able to induce
EMT in primary mouse and human hepatocytes add further
evidence for this concept. Furthermore, because HCV replicates in
hepatocytes, the fact that EMT could develop in HCV core-
expressing cells under TGF-b might provide a new notion to
explain the fibrotic effect of this virus.
In conclusion, our data ties together TGF-b and HCV which
are both known to be keys in the development of fibrosis and
HCC, highlight the ability of hepatocytes to develop EMT under
TGF-b and emphasize the role of HCV core protein in the
dynamic of these effects.
Moreover, one report has suggested EMT as a mechanism of
Epstein-Barr virus-related tumor cell dissemination [44]. Adeno-
viruses [45] or Papilloma viruses proteins have also been reported
to interact with Smad3-dependent transcription [46,47]. Overall,
our present results significantly reinforce the hypothesis that TGF-
b and EMT are important drivers of virus-induced human
cancers.
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